In two separate transactions, insurer Centene is divesting two of its pharmacy businesses, Magellan Rx and PANTHERx Rare. The company has signed two definitive agreement, and will sell the former to Prime Therapeutics and the latter to a consortium of the Vistria Group for a combined total of about $2.8 billion.
Centene divesting two pharmacy businesses for combined $2.8 billion
